Add yet another blow to GSK’s once-blockbuster diabetes drug, Avandia (rosiglitazone). The ongoing soap opera that is this drug’s manufacture and continued presence begins another chapter in its struggle to retain some semblance of competition in the pharma marketplace. Avandia’s troubles and brushes with near-market revocation are greater amidst news of the FDA considering axing its inclusion in a safety study involving itself and its much safer congener, Actos (pioglitazone).

The concerns over Avandia’s possible involvement in increasing death due to cardiovascular problems are legion and stretch back at least nine years, with its most recent actions coming this past February — as Senators Max Baucus (D-MT) and Charles Grassley (R- IA) released a report on the drug in February as well as a 2008 memorandum from two FDA drug safety reviewers who recommended pulling the drug from the U.S. market. | LINK

Related Posts Within Doctor Pundit:

1. FDA Considers Fate of Two Anti-Asthma Drugs Initially, this story wasn’t gaining much traction, but as the...
2. Report: Pharma Company Covered Up Known Cardiovascular Risks of Drug GSK (then known as SmithKline Beecham) knew in a 1999...
3. FDA Discussions on Avandia Enter 2nd Day As the debate over Avandia enters its second day, more...
4. FDA: Avandia Stays on Market The vote is 20-12 against withdrawing GSK’s troubled drug Avandia...
5. FDA Tells Pharma Co. to Halt Recruitment for Its Own Safety Trial Embattled pharma company GSK may be celebrating the continued availability...